Among them are antibodies antagonizing ICP molecules that play a key role in the inhibition of the anti-tumor immune responses (e.g., PD-1, CTLA-4, LAG-3, TIM3, etc.)or antibodies that target immunostimulatory molecules (e.g., OX40, GITR, CD137, etc.)(111, 112). Here, TNFRSF9 is linked to neoplasm.